BNGO · Bionano Genomics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $28.51M | $30.78M | $36.12M | $27.80M | $17.98M | $8.50M |
| Cost of Revenue | $15.32M | $30.40M | $26.55M | $21.86M | $14.11M | $5.73M |
| Gross Profit | $13.19M | $380.0K | $9.57M | $5.95M | $3.87M | $2.77M |
| R&D | $11.37M | $24.80M | $54.03M | $49.05M | $22.48M | $10.26M |
| SG&A | $35.15M | $51.85M | $93.50M | $88.60M | $58.49M | $31.07M |
| Total Operating Expenses | $46.52M | $104.36M | $224.81M | $137.64M | $80.97M | $41.32M |
| D&A | $9.53M | $14.02M | $13.71M | $9.62M | $3.35M | $1.48M |
| Operating Income | ($33.34M) | ($103.98M) | ($215.25M) | ($131.70M) | ($77.10M) | ($38.55M) |
| Interest Expense | - | - | $5.12M | $298.0K | $927.0K | $2.52M |
| Income Tax | $67.0K | $33.0K | $62.0K | $1.88M | ($5.72M) | $29.2K |
| Net Income | ($26.39M) | ($112.02M) | ($232.49M) | ($132.60M) | ($72.44M) | ($41.11M) |
| EPS - Basic | ($4.85) | ($88.13) | ($408.60) | ($156.00) | - | - |
| EPS - Diluted | ($4.85) | ($88.13) | ($408.60) | ($156.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.99M | $9.17M | $17.95M | $5.09M | $24.57M | $38.45M |
| Accounts Receivable | $5.20M | $4.75M | $9.32M | $7.02M | $4.93M | $2.78M |
| Inventory | $7.83M | $13.28M | $27.60M | $29.76M | $12.39M | $3.32M |
| Accounts Payable | $5.59M | $6.96M | $10.38M | $12.53M | $9.70M | $2.93M |
| Current Assets | $45.39M | $39.49M | $140.12M | $157.30M | $272.41M | $46.79M |
| Total Assets | $73.58M | $76.67M | $214.40M | $307.50M | $377.10M | $60.45M |
| Current Liabilities | $22.94M | $37.34M | $100.03M | $35.88M | $21.84M | $8.94M |
| Long-term Debt | - | - | - | - | $0 | $16.33M |
| Total Liabilities | $29.16M | $41.30M | $118.25M | $58.10M | $39.98M | $25.37M |
| Stockholders' Equity | $44.42M | $35.38M | $96.16M | $249.40M | $337.12M | $35.08M |
| Retained Earnings | ($719.62M) | ($693.23M) | ($581.21M) | ($348.71M) | ($216.12M) | ($143.68M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.34M) | ($68.92M) | ($125.18M) | ($124.82M) | ($71.93M) | ($38.31M) |
| Investing Cash Flow | ($12.75M) | $73.84M | $24.16M | $82.77M | ($278.06M) | ($2.45M) |
| Financing Cash Flow | $24.04M | ($13.69M) | $113.81M | $23.01M | $336.11M | $61.90M |
| CapEx | - | - | - | - | - | $0 |
| Free Cash Flow | - | - | - | - | - | ($38.31M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 46.3% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% |
| Operating margin | -116.9% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% |
| EBITDA margin | -83.5% | -292.3% | -558.0% | -439.1% | -410.2% | -436.0% |
| Net margin | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% |
| Free cash flow margin | - | - | - | - | - | -450.6% |
| FCF / Net income | - | - | - | - | - | 0.93 |
| R&D / Revenue | 39.9% | 80.6% | 149.6% | 176.4% | 125.0% | 120.6% |
| SG&A / Revenue | 123.3% | 168.5% | 258.9% | 318.7% | 325.3% | 365.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -35.9% | -146.1% | -108.4% | -43.1% | -19.2% | -68.0% |
| Return on equity | -59.4% | -316.7% | -241.8% | -53.2% | -21.5% | -117.2% |
| Return on invested capital | - | - | - | - | -18.1% | -59.2% |
| Liquidity | ||||||
| Current ratio | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 | 5.23 |
| Quick ratio | 1.64 | 0.70 | 1.12 | 3.55 | 11.91 | 4.86 |
| Cash ratio | 0.13 | 0.25 | 0.18 | 0.14 | 1.13 | 4.30 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.00 | 0.47 |
| Debt / Assets | - | - | - | - | 0.00 | 0.27 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -42.0x | -441.9x | -83.2x | -15.3x |
| Equity multiplier | 1.66 | 2.17 | 2.23 | 1.23 | 1.12 | 1.72 |
| Liabilities / Assets | 0.40 | 0.54 | 0.55 | 0.19 | 0.11 | 0.42 |
| Efficiency | ||||||
| Asset turnover | 0.39 | 0.40 | 0.17 | 0.09 | 0.05 | 0.14 |
| Inventory turnover | 1.96 | 2.29 | 0.96 | 0.73 | 1.14 | 1.73 |
| Days sales outstanding | 67d | 56d | 94d | 92d | 100d | 119d |
| Days inventory outstanding | 186d | 159d | 379d | 497d | 320d | 211d |
| Days payable outstanding | 133d | 84d | 143d | 209d | 251d | 187d |
| Cash conversion cycle | 120d | 132d | 331d | 380d | 170d | 144d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.2x | 0.6x | 40.3x | 972.2x | - | - |
| P / S | 0.3x | 0.7x | 107.2x | 8721.0x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -7.4% | -14.8% | 29.9% | 54.6% | 111.5% | -29.1% |
| Revenue CAGR (3y) | 0.8% | 19.6% | 61.9% | 32.3% | 23.7% | - |
| Revenue CAGR (5y) | 27.4% | 20.7% | 30.6% | - | - | - |
| Gross profit growth (YoY) | 3369.7% | -96.0% | 60.9% | 53.5% | 39.7% | -47.0% |
| Operating income growth (YoY) | 67.9% | 51.7% | -63.4% | -70.8% | -100.0% | -49.0% |
| Net income growth (YoY) | 76.4% | 51.8% | -75.3% | -83.1% | -76.2% | -37.9% |
| EPS growth (YoY) | 94.5% | 78.4% | -161.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | -29.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 25.6% | -63.2% | -61.4% | -26.0% | 860.9% | 870.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$28.51M totalReportable Segment$28.51M · 100.0%
Product / service
$55.25M totalProduct$26.74M · 48.4%
Consumable Revenue$13.97M · 25.3%
Software Revenue$6.41M · 11.6%
Instrument Revenue$6.36M · 11.5%
Product And Service Other$1.76M · 3.2%
Geographic
$28.51M totalEMEA$14.11M · 49.5%
Americas$12.18M · 42.7%
Asia Pacific$2.22M · 7.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-8.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Bionano Genomics against the 5 most active filers in the same SIC group.